What You Should Know:
– Arine – a next-generation medication intelligence company – and Gemini – a drug cost transparency platform – announced an integration that supports Blue Shield of California (Blue Shield) by combining each platform’s unique technology to deliver value-based care.
– The collaboration incorporates cost transparency information into Arine’s medication intelligence platform to empower care teams to provide highly personalized, data-driven medication consultations for Blue Shield members, which in turn resolves medication gaps while potentially lowering their out-of-pocket costs.
– Through an initial pilot, more than 30% of Blue Shield members who identified as non-adherent have already benefited from tailored interventions to improve adherence with cost savings alternatives.
Integration Enhances Delivery of Value-Based Care
The Arine-Gemini collaboration incorporates Gemini’s real-time, patient-specific benefits data into the Arine platform, which generates recommendations for targeted and personalized medication interventions. The integration of the two companies’ platforms enables safe and effective therapy at the lowest available costs. To date, more than a third of members identified as non-adherent have benefited from tailored interventions to improve adherence with cost savings alternatives.
“We are thrilled to collaborate with Gemini to help Blue Shield of California deliver affordable, accessible, and high-quality health care,” said Yoona Kim, PharmD, PhD, Arine’s co-founder and CEO. “Combining our complementary services allows Blue Shield care teams to provide members with data-driven recommendations that resolve medication gaps while potentially lowering member out-of-pocket costs.”
